OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
EPMT57

Enseval Putera Megatrading Tbk PT

PharmaceuticalsVerified

The company maintains a strong liquidity position with a current ratio of 2.18, indicating that it has more than twice the current assets to cover its current liabilities. Its liquidity is supported by a free cash flow of 266,777,476,690.001 IDR, which provides flexibility for reinvestment or debt servicing. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. In terms of profitability, the company generates a return on equity of 10.09% and a return on assets of 6.01%, which are metrics commonly used in the pharmaceutical industry to assess performance. These returns are compared against industry benchmarks to evaluate the company's efficiency in generating profits from its equity and assets. The company's revenue is concentrated in the health sector, with its business activities spanning digital platforms, distribution and sales, healthcare, marketing, and logistics. It offers a range of products, including consumer products, prescription and non-prescription medicines, raw materials, medical devices, clinics, and veterinary products. The company's growth trajectory is reflected in its recent revenue of 32,960,722,510,570.0 IDR, which is higher than the analyst estimate of 19,669,096,570,000 IDR. This suggests a positive growth trend, although the outlook for the next fiscal year will depend on market conditions and the company's strategic initiatives. The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The capital structure is supported by a low debt-to-equity ratio of 0.02, which suggests that the company is not heavily leveraged. However, the negative net cash position after subtracting total debt is a concern that may require monitoring. Recent events, such as the company's financial performance and market conditions, have influenced its current position. The company's capital expenditure of -231,097,027,520.0 IDR indicates a reduction in capital spending, which may be a strategic move to preserve cash or reallocate resources.

30-day price · EPMT+60.00 (+2.6%)
Low$2300.00High$2460.00Close$2380.00As of13 May, 00:00 UTC
Profile
CompanyEnseval Putera Megatrading Tbk PT
TickerEPMT.JK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. PT Enseval Putera Megatrading Tbk is an Indonesia-based integrated distribution and logistics service company in the health sector, engaged in the distribution and supply of pharmaceutical products, consumer products, medical equipment, cosmetics, and other trading products.

Classification. The company is classified under the Healthcare economic sector, Pharmaceuticals & Medical Research business sector, and Pharmaceuticals industry with a confidence level of 0.92.

The company maintains a strong liquidity position with a current ratio of 2.18, indicating that it has more than twice the current assets to cover its current liabilities. Its liquidity is supported by a free cash flow of 266,777,476,690.001 IDR, which provides flexibility for reinvestment or debt servicing. However, the company has a negative net cash position after subtracting total debt, which is a key liquidity flag. In terms of profitability, the company generates a return on equity of 10.09% and a return on assets of 6.01%, which are metrics commonly used in the pharmaceutical industry to assess performance. These returns are compared against industry benchmarks to evaluate the company's efficiency in generating profits from its equity and assets. The company's revenue is concentrated in the health sector, with its business activities spanning digital platforms, distribution and sales, healthcare, marketing, and logistics. It offers a range of products, including consumer products, prescription and non-prescription medicines, raw materials, medical devices, clinics, and veterinary products. The company's growth trajectory is reflected in its recent revenue of 32,960,722,510,570.0 IDR, which is higher than the analyst estimate of 19,669,096,570,000 IDR. This suggests a positive growth trend, although the outlook for the next fiscal year will depend on market conditions and the company's strategic initiatives. The company faces a medium liquidity risk, as indicated by the risk assessment, and a low dilution risk. The capital structure is supported by a low debt-to-equity ratio of 0.02, which suggests that the company is not heavily leveraged. However, the negative net cash position after subtracting total debt is a concern that may require monitoring. Recent events, such as the company's financial performance and market conditions, have influenced its current position. The company's capital expenditure of -231,097,027,520.0 IDR indicates a reduction in capital spending, which may be a strategic move to preserve cash or reallocate resources.
Key takeaways
  • The company has a strong liquidity position with a current ratio of 2.18.
  • The company generates a return on equity of 10.09% and a return on assets of 6.01%.
  • The company's revenue is concentrated in the health sector, with a diverse range of products and services.
  • The company's recent revenue of 32,960,722,510,570.0 IDR exceeds the analyst estimate, indicating a positive growth trend.
  • The company faces a medium liquidity risk and a low dilution risk, with a low debt-to-equity ratio of 0.02.
  • # RATIONALES
  • {
  • "margin_outlook_rationale": "The company's margin outlook is positive, driven by its strong liquidity position and efficient use of assets.",
Financial snapshot
PeriodHA-latest
CurrencyIDR
Revenue$32.96T
Gross profit$3.28T
Operating income$1.03T
Net income$789.19B
R&D
SG&A
D&A
SBC
Operating cash flow$833.36B
CapEx-$231.10B
Free cash flow$266.78B
Total assets$13.13T
Total liabilities$5.31T
Total equity$7.82T
Cash & equivalents
Long-term debt$189.93B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$7.82T
Net cash-$189.93B
Current ratio2.2
Debt/Equity0.0
ROA6.0%
ROE10.1%
Cash conversion1.1%
CapEx/Revenue-0.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricEPMTActivity
Op margin3.1%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin2.4%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin9.9%19.7% medp25 19.7% · p75 39.8%bottom quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-0.7%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity2.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Observations
IR observations
Last actual revenue19,669,096,570,000 IDR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 11:24 UTC#58ea0382
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 11:20 UTCJob: 5778fcc2